Friday, 08 October 2021 07:17 AM EDT
The U.S. Food and Drug Administration on Friday approved ChemoCentryx Inc's lead drug candidate, Avacopan, for treating a rare, fatal autoimmune disease, the biopharmaceutical company said.
© 2022 Thomson/Reuters. All rights reserved.
Receive breaking news and original analysis - sent right to your inbox.
The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.
Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.